What is Union Biometrica?
Founded in 1998, Union Biometrica operates as a critical provider of Large Particle Flow Cytometry technology. Unlike conventional cytometry platforms that struggle with fragile or oversized biological specimens, Union Biometrica has engineered a suite of advanced systems, including the COPAS and BioSorter product lines. These tools facilitate the automated, high-throughput analysis and gentle sorting of complex samples, such as stem cell clusters and model organisms like zebrafish embryos. By bridging the gap between manual observation and high-speed quantification, the company provides essential infrastructure for biotechnology firms and academic research institutions globally. Their commitment to precision and reproducibility has established them as a cornerstone in the field of advanced life science instrumentation.
How much funding has Union Biometrica raised?
Union Biometrica has raised a total of $816K across 2 funding rounds:
Debt
$350K
Debt
$466K
Debt (2020): $350K with participation from PPP
Debt (2021): $466K led by PPP
Key Investors in Union Biometrica
PPP
Public-Private Partnership
What's next for Union Biometrica?
With the successful acquisition of $466K, Union Biometrica is well-positioned to accelerate its market penetration and refine its technological roadmap. The company's strategic focus will likely center on expanding its footprint in North American and European markets while enhancing the sensitivity and throughput of its existing cytometry platforms. As the demand for high-fidelity biological data grows, Union Biometrica's ability to process delicate samples at scale provides a significant competitive advantage. Future growth will be driven by the integration of these capital resources into next-generation product development, ensuring the firm remains the primary choice for researchers requiring specialized, automated sorting solutions for complex biological models.
See full Union Biometrica company page
